JP2017506259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506259A5 JP2017506259A5 JP2016567288A JP2016567288A JP2017506259A5 JP 2017506259 A5 JP2017506259 A5 JP 2017506259A5 JP 2016567288 A JP2016567288 A JP 2016567288A JP 2016567288 A JP2016567288 A JP 2016567288A JP 2017506259 A5 JP2017506259 A5 JP 2017506259A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cml
- use according
- cki
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 61
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 38
- 239000003112 inhibitor Substances 0.000 claims description 35
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 33
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 33
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 22
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 17
- 229960002411 imatinib Drugs 0.000 claims description 17
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 17
- 102100034357 Casein kinase I isoform alpha Human genes 0.000 claims description 16
- 101000994700 Homo sapiens Casein kinase I isoform alpha Proteins 0.000 claims description 16
- 210000000601 blood cell Anatomy 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 210000000130 stem cell Anatomy 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 210000001185 bone marrow Anatomy 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- 102100037402 Casein kinase I isoform delta Human genes 0.000 claims description 9
- 101001026336 Homo sapiens Casein kinase I isoform delta Proteins 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 102100037398 Casein kinase I isoform epsilon Human genes 0.000 claims description 7
- 230000000779 depleting effect Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 6
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 6
- 206010066476 Haematological malignancy Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 4
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000004860 Blast Crisis Diseases 0.000 claims description 4
- 101710176553 Casein kinase I isoform epsilon Proteins 0.000 claims description 4
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 claims description 4
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims description 4
- 208000036676 acute undifferentiated leukemia Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 230000028617 response to DNA damage stimulus Effects 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 3
- 102000008122 Casein Kinase I Human genes 0.000 claims description 3
- 108010049812 Casein Kinase I Proteins 0.000 claims description 3
- 108010053889 Casein Kinase Ialpha Proteins 0.000 claims description 3
- 102000016929 Casein Kinase Ialpha Human genes 0.000 claims description 3
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims description 3
- 101001026376 Homo sapiens Casein kinase I isoform epsilon Proteins 0.000 claims description 3
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 150000003384 small molecules Chemical group 0.000 claims description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 2
- GJWAPAVRQYYSTK-UHFFFAOYSA-N [(dimethyl-$l^{3}-silanyl)amino]-dimethylsilicon Chemical compound C[Si](C)N[Si](C)C GJWAPAVRQYYSTK-UHFFFAOYSA-N 0.000 claims description 2
- 238000002617 apheresis Methods 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 229960002448 dasatinib Drugs 0.000 claims description 2
- 230000030279 gene silencing Effects 0.000 claims description 2
- 230000009368 gene silencing by RNA Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 201000010893 malignant breast melanoma Diseases 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 229960001346 nilotinib Drugs 0.000 claims description 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 230000002446 thrombocytic effect Effects 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934954P | 2014-02-03 | 2014-02-03 | |
| US61/934,954 | 2014-02-03 | ||
| PCT/IL2015/050118 WO2015114638A2 (en) | 2014-02-03 | 2015-02-03 | Method of eliminating stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017506259A JP2017506259A (ja) | 2017-03-02 |
| JP2017506259A5 true JP2017506259A5 (enExample) | 2018-03-22 |
Family
ID=52589722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567288A Pending JP2017506259A (ja) | 2014-02-03 | 2015-02-03 | 幹細胞を枯渇させるためのカゼインキナーゼｉ阻害剤の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20170042893A1 (enExample) |
| EP (1) | EP3102192A2 (enExample) |
| JP (1) | JP2017506259A (enExample) |
| CN (2) | CN111068053A (enExample) |
| AU (2) | AU2015212341A1 (enExample) |
| CA (1) | CA2937992A1 (enExample) |
| WO (1) | WO2015114638A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10722513B2 (en) | 2015-03-23 | 2020-07-28 | The University Of Melbourne | Treatment of respiratory diseases |
| US20190070183A1 (en) * | 2015-11-04 | 2019-03-07 | The Trustees Of Columbia University In The City Of New York | Targeting Casein Kinase-1 and PI3K/AKT/mTOR Pathways for Treatment of c-Myc-Overexpressing Cancers, Organ Transplant Associated Complications and Autoimmune Diseases |
| US10973820B2 (en) | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
| MX2021002652A (es) * | 2018-09-09 | 2021-09-23 | Qanatpharma Ag | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. |
| AU2019374731B2 (en) | 2018-11-07 | 2025-08-21 | Tianli Biotech Pty Ltd | Compounds and compositions for the treatment of respiratory diseases |
| TW202112368A (zh) * | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| CA2006008C (en) | 1988-12-20 | 2000-02-15 | Donald J. Kessler | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US20020123476A1 (en) | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
| US6933286B2 (en) | 1991-03-19 | 2005-08-23 | R. Martin Emanuele | Therapeutic delivery compositions and methods of use thereof |
| US6235887B1 (en) | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5721138A (en) | 1992-12-15 | 1998-02-24 | Sandford University | Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use |
| US5599703A (en) | 1993-10-28 | 1997-02-04 | The United States Of America As Represented By The Secretary Of The Navy | In vitro amplification/expansion of CD34+ stem and progenitor cells |
| US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
| WO2000009152A1 (en) | 1998-08-14 | 2000-02-24 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
| CA2305787A1 (en) | 2000-05-09 | 2001-11-09 | The University Of British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
| ATE258444T1 (de) | 1998-03-13 | 2004-02-15 | Univ British Columbia | Therapeutische chemokine rezeptor antagonisten |
| CA2245224A1 (en) | 1998-08-14 | 2000-02-14 | Jiang-Hong Giong | Chemokine receptor antagonists and chemotherapeutics |
| CA2328457A1 (en) | 1998-06-20 | 1999-12-29 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| US6512102B1 (en) * | 1998-12-31 | 2003-01-28 | Chiron Corporation | Compositions and methods of diagnosis and treatment using casein kinase I |
| IL151079A0 (en) * | 2000-02-07 | 2003-04-10 | Quark Biotech Inc | Fas pathway genes |
| ATE265219T1 (de) | 2000-05-09 | 2004-05-15 | Univ British Columbia | Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten |
| AU2001284419A1 (en) | 2000-09-05 | 2002-03-22 | Seikagaku Corporation | Novel polypeptides and anti-hiv drugs containing the same |
| WO2002094864A2 (en) | 2001-05-25 | 2002-11-28 | Genset S.A. | Human cdnas and proteins and uses thereof |
| US20050171005A1 (en) * | 2002-04-29 | 2005-08-04 | Yinon Ben-Neriah | Methods and compositions for modulating beta-catenin phosphorylation |
| EP2426139B1 (en) | 2002-08-27 | 2014-10-01 | Biokine Therapeutics Ltd. | CXCR4 antagonist and use thereof |
| DE10240064A1 (de) | 2002-08-30 | 2004-03-11 | Universitätsklinikum Freiburg | CXCR4-Rezeptor-Antagonisten |
| US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
| JP2006524242A (ja) | 2003-03-27 | 2006-10-26 | エモリー ユニバーシティー | Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法 |
| US7291631B2 (en) | 2003-04-11 | 2007-11-06 | Genzyme Corporation | CXCR4 chemokine receptor binding compounds |
| EP1697715A4 (en) | 2003-12-05 | 2007-10-10 | Univ Leland Stanford Junior | IDENTIFICATION, ISOLATION AND ELIMINATION OF CANCER STEM CELLS |
| WO2006002119A2 (en) | 2004-06-18 | 2006-01-05 | Gpc Biotech, Inc. | Kinase inhibitors for treating cancers |
| TW200628156A (en) * | 2004-11-04 | 2006-08-16 | Bristol Myers Squibb Co | Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases |
| MX2009011878A (es) | 2007-05-01 | 2010-01-25 | Enzon Pharmaceuticals Inc | Compuestos antagonistas de acido ribonucleico para la modulacion de beta-catenina. |
| FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| US9623109B2 (en) * | 2008-05-27 | 2017-04-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of killing cells and use of same in prevention and treatment of cancer |
| CZ2012538A3 (cs) | 2012-08-08 | 2014-02-19 | Masarykova Univerzita | Inhibitory pro léčbu B-buněčné chronické lymfocytární leukémie |
-
2015
- 2015-02-03 CN CN201911074476.9A patent/CN111068053A/zh active Pending
- 2015-02-03 CN CN201580018179.6A patent/CN106470699A/zh active Pending
- 2015-02-03 WO PCT/IL2015/050118 patent/WO2015114638A2/en not_active Ceased
- 2015-02-03 US US15/115,712 patent/US20170042893A1/en not_active Abandoned
- 2015-02-03 JP JP2016567288A patent/JP2017506259A/ja active Pending
- 2015-02-03 CA CA2937992A patent/CA2937992A1/en not_active Abandoned
- 2015-02-03 AU AU2015212341A patent/AU2015212341A1/en not_active Abandoned
- 2015-02-03 EP EP15706542.6A patent/EP3102192A2/en not_active Withdrawn
-
2018
- 2018-12-20 US US16/228,630 patent/US20190365754A1/en not_active Abandoned
-
2020
- 2020-06-05 AU AU2020203715A patent/AU2020203715A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506259A5 (enExample) | ||
| Ladikou et al. | Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia | |
| Gangadhar et al. | The role of chemokine receptor CXCR4 in lung cancer | |
| IL186104A (en) | Phosphoramidate History of Nucleoside Compounds | |
| FI3694529T3 (fi) | Trispesifiset proteiinit ja niiden käyttömenetelmät | |
| JP2019506403A5 (enExample) | ||
| BR112015025711A8 (pt) | uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer | |
| EP2308885A3 (en) | Novel compounds and methods for therapy | |
| KR20150080592A (ko) | Tec 패밀리 키나제 억제제 애쥬번트 요법 | |
| Blomberg et al. | Randomized trials of systemic medically-treated malignant mesothelioma: a systematic review | |
| JP2020505433A5 (enExample) | ||
| Gong et al. | Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice | |
| JP2018522038A5 (enExample) | ||
| EP3895725A3 (en) | A method for treating tumor by using recombinant interferon with changed spatial configuration | |
| Roganovic | Acute lymphoblastic leukemia in children | |
| Wang et al. | β-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia | |
| CN111868059A (zh) | 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂 | |
| Ottmann et al. | Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia | |
| Cuglievan et al. | Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community | |
| Du et al. | Recent advancements of bortezomib in acute lymphocytic leukemia treatment | |
| JP2017519006A5 (enExample) | ||
| Cai et al. | Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response | |
| JP2013511487A (ja) | Ｃｄｃ７阻害剤と抗新生物薬とを含む治療用の組み合わせ | |
| WO2017069288A8 (en) | Pharmaceutical composition for use in treating aml and method of treating aml in a subject in need thereof | |
| O’Connor et al. | The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study |